Xiaojing Yan
Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Ruijin Hospital(CN)First Hospital of China Medical University(CN)Shanghai Institute of Hematology(CN)China Medical University(CN)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, Multiple Myeloma Research and Treatments, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research
Most-Cited Works
- → COVID‐19 metabolism: Mechanisms and therapeutic targets(2022)43 cited
- → Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study(2025)2 cited
- → SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial(2024)1 cited
- → Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma(2025)1 cited
- → Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China(2025)
- → Abstract CT025: JS203, a CD20×CD3 bispecific antibody with a 2:1 structure, demonstrated promising responses in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) in a phase I study(2025)